BVF Inc’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-3,133,224
| Closed | -$11.6M | – | 50 |
|
|
2017
Q4 | $11.6M | Hold |
3,133,224
| – | – | 1.4% | 23 |
|
|
2017
Q3 | $12.8M | Hold |
3,133,224
| – | – | 1.63% | 21 |
|
|
2017
Q2 | $11.6M | Hold |
3,133,224
| – | – | 1.81% | 18 |
|
|
2017
Q1 | $13M | Hold |
3,133,224
| – | – | 2.21% | 16 |
|
|
2016
Q4 | $13.5M | Sell |
3,133,224
-4
| -0% | -$26 | 2.71% | 12 |
|
|
2016
Q3 | $30.8M | Hold |
3,133,228
| – | – | 5.81% | 5 |
|
|
2016
Q2 | $17.7M | Hold |
3,133,228
| – | – | 3.78% | 10 |
|
|
2016
Q1 | $23.9M | Hold |
3,133,228
| – | – | 5.91% | 5 |
|
|
2015
Q4 | $41.7M | Buy |
3,133,228
+406,472
| +15% | +$7M | 7.11% | 5 |
|
|
2015
Q3 | $44.8M | Buy |
2,726,756
+1,101,060
| +68% | +$22.6M | 9.06% | 3 |
|
|
2015
Q2 | $36.5M | Sell |
1,625,696
-760,000
| -32% | -$12M | 6.44% | 6 |
|
|
2015
Q1 | $23.3M | Buy |
2,385,696
+91,986
| +4% | +$902K | 4.88% | 7 |
|
|
2014
Q4 | $26.1M | Buy |
2,293,710
+649,164
| +39% | +$7.05M | 5.09% | 6 |
|
|
2014
Q3 | $18.9M | Buy |
1,644,546
+1,500
| +0.1% | +$22.9K | 3.93% | 7 |
|
|
2014
Q2 | $31.9M | Buy |
1,643,046
+142,750
| +10% | +$2.52M | 5.05% | 6 |
|
|
2014
Q1 | $26.9M | Hold |
1,500,296
| – | – | 4.17% | 9 |
|
|
2013
Q4 | $15.8M | Buy |
1,500,296
+21,500
| +1% | +$240K | 2.77% | 9 |
|
|
2013
Q3 | $18.3M | Buy |
1,478,796
+129,916
| +10% | +$1.37M | 3.14% | 8 |
|
|
2013
Q2 | $12.6M | Buy |
+1,348,880
| New | +$17.3M | 2.45% | 9 |
|
BVF Inc's CASC Position: Q1 2018 in Review
BVF Inc sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 3,133,224 shares — an estimated $11.6M sold.
BVF Inc first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $44.8M in Q3 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- BVF Inc reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- BVF Inc sold 3,133,224 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $11.6M.
- BVF Inc first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- BVF Inc's Cascadian Therapeutics, Inc. position peaked at $44.8M in Q3 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on BVF Inc's 13F filing for Q1 2018, filed 7 May 2018.